

U.S.S.N. 08/359,937  
Filed: December 20, 1994  
*Amendment*

### Remarks

As discussed with the Examiner, the composition claims 1-12, 15 and 16, have been cancelled. These are being filed in a divisional application. A Terminal Disclaimer to the previously issued patent, U.S. Patent No. 5,204,108, will be filed in the divisional application. Nothing in the issued patent relates to methods of nasal delivery, only compositions, which have now been demonstrated to be different from those described in the prior art.

All claims now depend on independent claim 17. Claim 17 has been amended to define the material forming the microspheres as comprising the materials described in the application at page 5, line 1, to page 6, line 5, (where the terms starch and dextran include the derivatives recited in dependent claim 28 and described at page 5, lines 15-30). Claim 17 has also been amended to recite that the drug is either a protein or peptide or one of the recited classes of drugs described at page 14, lines 9-30, which excludes sodium chromoglycate.

F

U.S.S.N. 08/359,937  
Filed: December 20, 1994  
*Amendment*

Allowance of claims 13, 14, and 17-28, as amended, is earnestly solicited. A copy of all claims as pending upon entry of this amendment is attached to facilitate review by the examiner.

Respectfully submitted,



Patrea L. Pabst, Esq.  
Registration No. 31,284


Date: May 14, 1997

ARNALL GOLDEN & GREGORY  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8798 4  
(404) 873-8599 (fax)

#### CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the enclosed Transmittal Letter is being facsimile transmitted to the U. S. Patent and Trademark Office on the date shown below.

Date: May 14, 1997



Patricia Hilger